Nanocarriers have received special attention in biomedicine for the treatment of various
diseases, especially cancer, as one of the leading causes of death worldwide. Nanocarriers …

The inception of cancer treatment with chemotherapeutics began in the 1940s with nitrogen
mustards that were initially employed as weapons in World War II. Since then, treatment …

Phosphoglycerate dehydrogenase (PHGDH), the rate-limiting enzyme in the first step of the
serine synthesis pathway (SSP), is overexpressed in multiple types of cancers. The …

The functional role of microRNA-375 (miR-375) in the development of prostate cancer (PCa)
remains controversial. Previously, we found that plasma exosomal miR-375 is significantly …

The refractory of castration-resistant prostate cancer (CRPC) is mainly reflected in drug
resistance. The current research on the resistance mechanism of CRPC is still in its infancy …

Abstract Glucocorticoid (GC)‐induced osteoporosis (GIO) is a concurrent disease commonly
appeared in chronic inflammatory and autoimmune disease patients. Stereoselective …

Inflammation is a multifactorial process and various biological mechanisms and pathways
participate in its development. The presence of inflammation is involved in pathogenesis of …

Enzalutamide (Enz) is a next-generation androgen receptor (AR) antagonist used to treat
castration-resistant prostate cancer (CRPC). Unfortunately, the relapsing nature of CRPC …

Prostate cancer (PCa) is the second most common and fifth most aggressive neoplasm
among men worldwide. In the last decade, extracellular vesicle (EV) research has decoded …

Hippo signaling restricts tumor growth by inhibiting the oncogenic potential of YAP/TAZ‐
TEAD transcriptional complex. Here, we uncover a context‐dependent tumor suppressor …